Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$6.68
-$2.78(-6.79%)
At close: 4:00 PM EST
$6.68
-$2.78(-6.79%)
Day’s Range― - ―
52-Week Range$4.80 - $13.69
Previous CloseN/A
Volume178.18K
Average Volume (3M)86.97K
Market Cap
$32.67M
Enterprise Value$7.31M
Total Cash (Recent Filing)$55.08M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Jul 30, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,388,223
10 Day Avg. Volume122,947
30 Day Avg. Volume86,969
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$72.50Price Target Upside985.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.68
Revenue Forecast (FY)$17.50M
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ProgressFast Track status and an independent board's decision to expand a Phase 2 cohort are durable de-risking events: they can accelerate development timelines, improve regulatory dialogue, and signal tolerability/efficacy potential. This strengthens Aligos's program viability and competitive position in HBV long-term.
Non-dilutive Regional PartnershipThe Amoytop licensing deal provides immediate non-dilutive capital, milestone upside, and shifts development/commercial risk in Greater China to a well-capitalized partner. Structurally this extends runway, concentrates internal resources on ex-China rights, and leverages local expertise for faster regional execution.
Underlying Gross ProfitabilityHigh gross margins indicate attractive underlying product economics once a candidate reaches commercial scale. Persistently strong gross profitability supports sustainable margins long-term if revenues increase and R&D/SG&A are managed, improving cash conversion potential on commercialization.
Bears Say
Persistent Cash BurnConsistent heavy negative cash flow is a durable constraint: it forces dependence on financing, partnerships, or asset sales to fund trials. That ongoing burn increases dilution risk, limits strategic optionality, and can slow or force reprioritization of development programs absent material revenue or large partner funding.
Large Operating & Net LossesSustained large operating and net losses erode equity and restrict reinvestment capacity. Over time this can weaken the balance sheet, raise financing costs, and pressure management to cut programs or seek partnering/dilution, hindering the firm's ability to pursue multiple late-stage opportunities concurrently.
Volatile, Small Revenue BaseA small, volatile revenue base limits self-funding of clinical development and makes forecasting and strategic planning difficult. Structural reliance on milestone/license payments or capital raises raises execution risk and can delay scaling commercial capabilities even if clinical programs succeed.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $4.80 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Aligos Therapeutics’s market cap is $32.67M.
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on May 07, 2026. The company reported -$2.21 earnings per share for the quarter, beating the consensus estimate of -$2.213 by $0.003.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate is -1.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 5,388,223 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$2.21 in its last earnings report, beating expectations of -$2.213. Following the earnings report the stock price went up 6.799%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (985.33% Upside)
$72.50 (985.33% Upside)
Hedge Fund Trend
Decreased
By 111.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 61.3%
Last 30 Days ▲ 61.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.55%
12-Months-Change
Fundamentals
Return on Equity
-139.47%
Trailing 12-Months
Asset Growth
-57.16%
Trailing 12-Months
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(985.33% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―